Lookup NU author(s): Dr David Sheridan,
Dr R Neely,
Professor Margaret Bassendine
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
The six different HCV-genotypes have marked differences in response to therapy with pegylated interferon-α and ribavirin. The introduction of the direct acting antiviral (DAA) protease inhibitors, telaprevir and boceprevir in combination with pegylated interferon-α and ribavirin has become the new standard of care for genotype 1 infection. Several host factors associated with response to pegylated interferon-α and ribavirin are not as important in predicting response to triple therapy, and yet low-density lipoprotein cholesterol (LDLC) and statin use remain important associations of outcome with DAAs. This review focuses on the clinical associations between lipids and treatment response to interferon based antiviral treatments. We consider how understanding the interactions of HCV and host lipid metabolism remains relevant in the era of DAAs for genotype 1 infection and for treatment of non-genotype 1 chronic hepatitis C.
Author(s): Sheridan DA, Neely RD, Bassendine MF
Publication type: Review
Publication status: Published
Journal: Clinics and Research in Hepatology and Gastroenterology
Print publication date: 01/02/2013
ISSN (print): 2210-7401
ISSN (electronic): 2210-741X
PubMed id: 22959093